Godavari Biorefineries Q1 FY27: Revenue Up to ₹559.9 Cr, PAT at ₹(19.3) Cr
Godavari Biorefineries reported Q1 FY27 total income of ₹559.9 crore, up from ₹534.0 crore in Q1 FY26. The company incurred a PAT of ₹(19.3) crore. Key developments include commissioning a 200 KLPD grain-based distillery, increasing total ethanol capacity to 800 KLPD, and filing for preliminary efficacy trials for an anti-cancer molecule.
The commissioning of a new distillery and progress in drug discovery are positive long-term developments. However, the reported net loss and decreased EBITDA suggest short-term challenges that may moderate the immediate impact.
The company reported an increase in total income but a decrease in EBITDA and a net loss for the quarter. While strategic expansions and innovation milestones were achieved, the financial performance indicates mixed results.
Godavari Biorefineries Limited announced its unaudited financial results for the quarter ended June 30, 2026, following Board approval. The company reported total income of ₹559.9 crore for Q1 FY27, an increase from ₹534.0 crore in Q1 FY26. However, EBITDA stood at ₹2.6 crore, a decrease from ₹6.5 crore in the prior year's quarter, and the company registered a Profit After Tax (PAT) of ₹(19.3) crore for Q1 FY27, compared to ₹(16.0) crore in Q1 FY26.
During the quarter, the company commissioned its 200 KLPD grain-based distillery at Sameerwadi, increasing its total ethanol capacity to 800 KLPD. This expansion aims to enhance feedstock flexibility and optimize operations. The Bio-based Chemicals business showed robust revenue growth and margin expansion, driven by debottlenecking initiatives and a focus on specialty products. The company also secured an Indian patent for a cost-effective process to manufacture branched alcohols.
In its innovation pipeline, Godavari Biorefineries filed with the CDSCO to initiate preliminary efficacy trials for its lead anti-cancer molecule, with trials expected to commence from Q3 FY27, subject to regulatory approvals. Shri Samir Somaiya, CMD, highlighted the strategic execution and operational milestones, emphasizing the strengthening of the integrated platform and the focus on high-value Bio-based Chemicals, strategic partnerships, and commercializing innovation-led products. The company aims to capitalize on India's evolving biofuel landscape and R&D efforts for sustainable long-term growth and value creation.
What to do with a filing like this
Godavari Biorefineries Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Godavari Biorefineries Limited. Read the original for the full detail.